Milk Phospholipids a New Ingredient for Formulation of Functional Foods with Bioactivity
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
UNITED STATES PATENT of FICE 2,262,743 PROCESS for BREAKING PETROLEUR EMUSIONS Melvin De Groote, University City, and Bernhard Keiser and Charles M
Patented Nov. 11, 1941 2,262,743 UNITED STATES PATENT of FICE 2,262,743 PROCESS FOR BREAKING PETROLEUR EMUSIONS Melvin De Groote, University City, and Bernhard Keiser and Charles M. Blair, Jr., Webster Groves, Mo., assignors to Petroite Corporation, Ltd., Wilmington, Del, a corporation of Dela Ware No Drawing. Application May 12, 194i, Serial No. 393,128 4 Claims. (C1. 252-344) This invention relates primarily to the resolu ous chemical compounds adapted for use in tion of petroleum emulsions, our present appli breaking oil field emulsions, reference was made cation being a continuation, in part, of Our co to a type exemplified by the following formula: pending application Serial No. 342,716, filed June. N-CH 27, 1940. 2 One object of our invention is to provide a Ciuc, novel process for resolving petroleum emulsions NH-CI of the water-in-oil type that are commonly re In regard to such compounds, it is pointed out ferred to as 'cut oil,' 'roily oil,' 'emulsified oil,' in said co-pending application Serial No. 342,716, etc., and which comprise fine droplets of nat 10 that the oxyalkylated derivatives may be emi urally-occurring waters or brines dispersed in a ployed, This fact is stated in the following.lan more or less permanent state throughout the oil guage: which constitutes the continuous phase of the "Also, as is well known, any of the diamines emulsion. w of the kind previously described containing at Another object of our invention is to provide s least one amino hydrogen atom may be con a: economical and rapid process for separating verted into hydroxylated derivatives by reaction emulsions which have been prepared under con with an alkylene oxide, such as ethylene oxide, trolled conditions from mineral oil, such as crude propylene Oxide, glycidol, epichlorhydrin, and the petroleum and relatively soft waters or weak like. -
Trans Fat Free by 2023 CASE STUDIES in Trans Fat Elimination
Trans Fat Free by 2023 CASE STUDIES in Trans Fat Elimination YEARS 2009-2019 Edited by NCD Alliance, May 2019 Cover images and page 4, 22: © shutterstock Pages 8: © stock.adobe.com Page 16: Kim Jones Page 30: © REUTERS / Finbarr O’Reilly / stock.adobe.com Page 35: Paralela NCD Alliance | 31-33 Avenue Giuseppe Motta | 1202 Geneva, Switzerland www.ncdalliance.org Table of contents Executive Summary 4 Background 4 Country-Specific Case Studies 5 Key Conclusions 6 Taking Action – What Needs to Happen 7 The NCD Alliance calls on governments to: 7 Introduction 8 Goals of the Report 8 Methodology 9 Background on Trans Fats and Policy Strategies 10 What Are TFAs? 10 Health Harms of TFA Consumption 10 World Health Organization Recommendations 11 Strategies to Reduce TFA Consumption 12 The First TFA Limit 12 Current Status of TFA Policies 12 Map of countries and territories that have enacted a TFA limit or PHO ban 14 Country-Specific Case Studies 16 Chile 16 Saudi Arabia 19 Slovenia 22 South Africa 25 Thailand 27 United States of America 29 Key Conclusions 32 Acknowledgements 36 Additional Information 38 References 39 Trans Fat Free by 2023 Case Studies in Trans Fat Elimination Executive Summary Background Industrially-produced trans fatty acids (TFAs),a This report presents case studies of six countries common in baked goods, pre-packaged foods in different regions of the world that have enacted and some cooking oils, are a major contributor to policies to eliminate TFAs from their food supply, cardiovascular diseases (CVD) and noncommunicable as recommended by WHO.4 The purpose of this diseases (NCDs) worldwide,1 estimated to contribute report is to provide civil society organisations to more than half a million deaths each year.2 TFAs (CSOs), including national and regional NCD have no known health benefits and can be replaced alliances, and policy-makers around the world with in foods without impacting their consistency or taste. -
WO 2019/008101 Al 10 January 2019 (10.01.2019) W !P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/008101 Al 10 January 2019 (10.01.2019) W !P O PCT (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61K 9/28 (2006 .0 1) A61K 31/198 (2006 .0 1) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, A61K 9/50 (2006 .0 1) A61K 31/202 (2006 .0 1) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (21) International Application Number: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, PCT/EP20 18/068261 KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 05 July 2018 (05.07.2018) Published: — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201731023754 06 July 2017 (06.07.2017) 17186984.5 2 1 August 2017 (21.08.2017) (71) Applicant: EVONIK TECHNOCHEMIE GMBH [DE/DE]; GutenbergstraBe 2, 69221 Dossenheim (DE). (72) Inventors: GUHA, Ashish; Excellencia - A, 803 Casabel- la Shil-road, Mumbai, Dombivali (E) 421204 (IN). KAN- ERIA, Vishal; Rajkamal Bayside - 2/504, Sector 15, Palm Beach Road, CBD Belapur, Navi Mumbai 400614 (IN). JOSHI, Shraddha; Flat no 1203, 13th floor, Newa Gar den, Phase 1, Sector 20A, Plot 1, Airoli, Navi Mumbai 400708 (IN). BHOSALE, Suraj; A-1902, CIELO, LOD- HA Splendora, Bhayenderpada, Ghodbunder road, Thane (W) 400607 (IN). -
Letter Reso 1..5
*LRB10013159MST27555r* SR0637 LRB100 13159 MST 27555 r 1 SENATE RESOLUTION 2 WHEREAS, The members of the Illinois Senate are saddened to 3 learn of the death of Fred August Kummerow of Urbana, who 4 passed away on May 31, 2017; and 5 WHEREAS, Fred Kummerow was born in Berlin, Germany to 6 Helene Rieck and August Kummerow on October 4, 1914, while his 7 father was away in the German Army fighting the Russians on the 8 Eastern Front; in 1923, at the age of eight, he and his family 9 emigrated to the United States; he began school in Milwaukee, 10 Wisconsin, not speaking a word of English; he graduated from 11 Boys Technical High School in Milwaukee in 1933; and 12 WHEREAS, Fred Kummerow was employed at Yahr Lange Drug & 13 Cosmetic Company, working 48-hours a week and taking night 14 classes four nights a week at the Milwaukee branch of the 15 University of Wisconsin, which was enough to make him a 16 sophomore at the University of Wisconsin-Madison when he began 17 there in September of 1936; he graduated with a Bachelor of 18 Science in Chemistry in 1939; he started his graduate work with 19 Professor Harry Steenbok, the discoverer of Vitamin D; he was 20 awarded a Master of Science in 1941 and a Ph.D. in 1943, both 21 in Biochemistry; and 22 WHEREAS, Fred Kummerow married Amy Louise Hildebrand on SR0637 -2- LRB100 13159 MST 27555 r 1 June 24, 1942; in the Fall of 1943, they left Madison for a 2 National Research Council job at Clemson University in South 3 Carolina; the job aimed to eradicate pellagra, a disease caused 4 by the lack -
Federal Register/Vol. 78, No. 217
Federal Register / Vol. 78, No. 217 / Friday, November 8, 2013 / Notices 67169 Brookings Institution event Web site at SUMMARY: Based on new scientific component of these oils. This document http://www.brookings.edu//health/ evidence and the findings of expert addresses PHOs because they are the events. scientific panels, the Food and Drug primary dietary source of industrially- Transcripts: Please be advised that Administration (FDA) has tentatively produced trans fat (Ref. 1). Although all transcripts will not be available. determined that partially hydrogenated refined edible oils contain some trans SUPPLEMENTARY INFORMATION: On July 9, oils (PHOs), which are the primary fat as an unintentional byproduct of 2012, the President signed into law the dietary source of industrially-produced their manufacturing process, trans fats Food and Drug Administration Safety trans fatty acids, or trans fat, are not are an integral component of PHOs and and Innovation Act (FDASIA) (Pub. L. generally recognized as safe (GRAS) for are purposely produced in these oils to 112–144). Title I of FDASIA any use in food based on current affect the properties of the oil and the reauthorizes PDUFA and provides FDA scientific evidence establishing the characteristics of the food to which they with the user fee resources necessary to health risks associated with the are added. maintain an efficient review process for consumption of trans fat, and therefore The current scientific evidence, human drug and biological products. that PHOs are food additives. Although which is discussed in section IV of this The reauthorization of PDUFA includes FDA has not listed the most commonly document, identifies significant health performance goals and procedures for used PHOs, they have been used in food risks caused by the consumption of the Agency that represent FDA’s for many years based on self- trans fat. -
Wise Traditions
Wise Traditions IN FOOD, FARMING AND THE HEALING ARTS A PUBLICATION OF Volume 13 Number 1 T HE W ESTON A. PRICE FOUND at ION ® Spring 2012 CONTENTS FEATURES Good Fats, Bad Fats Page 16 All Thumbs Book Reviews Page 46 Chris Masterjohn separates fact from fiction Odd Bits Tending the Wild The China Study Myth Page 23 Beyond Broccoli Denise Minger debunks the The Happiness Diet vegan conclusions The Polluters Salt and Our Health Page 28 Tim's DVD Reviews Page 52 Morton Satin, PhD, describes the folly Tim Boyd reviews great new videos of salt reduction measures Growing Wise Kids Page 55 Jen Allbritton, CN, on sustenance from soup DEPARTMENTS President’s Message Page 2 Soy Alert Page 60 Mythbusters Kaayla Daniel, PhD, on soy and the link to thyroid disease Letters Page 3 Legislative Update Page 65 Caustic Commentary Page 13 Judith McGeary on raw milk defense at the Sally Fallon Morell challenges policy level the Diet Dictocrats A Campaign for Real Milk Page 69 The Dietitian's Experience Page 39 Testimony by David Gumpert at the Kim Rodriguez, RD, takes us to a Harvard raw milk debate children's psychiatric hospital Raw Milk Updates Page 72 Healthy Baby Gallery Page 76 Homeopathy Journal Page 43 Local Chapters Page 79 Joette Calabrese describes treatments Shop Heard ‘Round the World Page 92 for urinary tract infections Membership Page 116 Upcoming Events Page 117 89494_text.indd 1 3/19/12 11:36 AM THE WESTON A. PRICE President’s Message FOUNDatION ® Education Research Activism BOARD OF DIRECTORS Sally Fallon Morell, MA, President and Treasurer Kaayla T. -
Co-Olefinic Fatty Acids
SOME STUDIES ' N FATTY ACID SER ES PART TWO CO-OLEFINIC FATTY ACIDS NATIONAL CHEMICAL LABORATORY, POONA- 8. - (1965 ) C 0 T E T S Page CHAPTER I limOiXJCTION 25-34 w-Olefinic fatty acids 25 Methods of synthesis 25 Methods utilising components 28 in which the co-olefinic group is already present. Methods in which the w-olefinic 30 group is produced by an elimiaation reaction. Other methods 31 References 33 CHAPTER II PYROLYSIS OF MAiiY-MEMBERED 36 - 130 LACTONESj A UEJJHIAL METHOD 1T(B THE SYNTHESIS OF «-0LEFiiac f a t t y a c i d s . Preliminary investigations 36 Pyrolysis of many-membered 43 lactones Preparation of ^J^-hydroxy 45 fatty acids Preparation of lactones 52 Pyrolysis of lactones 62 Discussion 67 Experimental 75 Summary 126 References 127 Page CHAPTER III SYSrmTIC 131 - 153 CHAM-SHOHTENIiia OF W-OLEb*INIC f a t t y a c id s Chain-shortening by 132 one carbon Chain-shortening 133 two carbons Chain-shortening by 136 three carbons Experimental 141 Summary 150 References 151 CHAPTER I INTRODUCTION 2 5 oj-OLH^’INIC FATTY AGIDS I.{TRQJUCTIQN The work described in this Part deals with the development of general method for the preparation of long chain co-olefinic fatty acids. cu-Olefinic acids offer an unique opportunity for degrading the molecule from one end in bits of one or more carbon atoms at a time. This work was of interest in comiection with the possible utilization of kamlolenic acid: H0CH2(CH2)3CH=CHCH=CH-CH=CH(CH2)7C00H the major component of the o il from the seeds of Mallotus phllippinensis. -
WO 2013/184908 A2 12 December 2013 (12.12.2013) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/184908 A2 12 December 2013 (12.12.2013) P O P C T (51) International Patent Classification: Jr.; One Procter & Gamble Plaza, Cincinnati, Ohio 45202 G06F 19/00 (201 1.01) (US). HOWARD, Brian, Wilson; One Procter & Gamble Plaza, Cincinnati, Ohio 45202 (US). (21) International Application Number: PCT/US20 13/044497 (74) Agents: GUFFEY, Timothy, B. et al; c/o The Procter & Gamble Company, Global Patent Services, 299 East 6th (22) Date: International Filing Street, Sycamore Building, 4th Floor, Cincinnati, Ohio 6 June 2013 (06.06.2013) 45202 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/656,218 6 June 2012 (06.06.2012) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: THE PROCTER & GAMBLE COMPANY HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, [US/US]; One Procter & Gamble Plaza, Cincinnati, Ohio KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 45202 (US). MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (72) Inventors: XU, Jun; One Procter & Gamble Plaza, Cincin SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, nati, Ohio 45202 (US). -
[Docket No. FDA-2013-N-1317] Final Determination
This document is scheduled to be published in the Federal Register on 06/17/2015 and available online at http://federalregister.gov/a/2015-14883, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2013-N-1317] Final Determination Regarding Partially Hydrogenated Oils AGENCY: Food and Drug Administration, HHS. ACTION: Notice; declaratory order. SUMMARY: Based on the available scientific evidence and the findings of expert scientific panels, the Food and Drug Administration (FDA or we) has made a final determination that there is no longer a consensus among qualified experts that partially hydrogenated oils (PHOs), which are the primary dietary source of industrially-produced trans fatty acids (IP-TFA) are generally recognized as safe (GRAS) for any use in human food. This action responds, in part, to citizen petitions we received, and we base our determination on available scientific evidence and the findings of expert scientific panels establishing the health risks associated with the consumption of trans fat. DATES: Compliance date: Affected persons must comply no later than June 18, 2018. FOR FURTHER INFORMATION CONTACT: Mical Honigfort, Center for Food Safety and Applied Nutrition (HFS-265), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 240-402-1278, email: [email protected]. SUPPLEMENTARY INFORMATION: Table of Contents 2 I. Background II. Definitions and Scope, and Related Comments With FDA Responses III. Discussion of Legal Issues, and Related Comments With FDA Responses A. GRAS B. Prior Sanctions C. Procedural Requirements IV. Discussion of Scientific Issues, and Related Comments With FDA Responses A. -
Valorization of Tomato Processing By-Products: Fatty Acid Extraction and Production of Bio-Based Materials
materials Article Valorization of Tomato Processing by-Products: Fatty Acid Extraction and Production of Bio-Based Materials José J. Benítez 1,* , Paula M. Castillo 1, José C. del Río 2 , Manuel León-Camacho 3, Eva Domínguez 4 , Antonio Heredia 4,5, Susana Guzmán-Puyol 6, Athanassia Athanassiou 6 and José A. Heredia-Guerrero 6,* 1 Instituto de Ciencia de Materiales de Sevilla, Centro Mixto CSIC-Universidad de Sevilla, Américo Vespucio 49, E-41092 Seville, Spain; [email protected] 2 Instituto de Recursos Naturales y Agrobiología de Sevilla-CSIC, Avenida Reina Mercedes 10, 41012 Seville, Spain; [email protected] 3 Instituto de la Grasa, CSIC, 41006 Seville, Spain; [email protected] 4 Instituto de Hortofruticultura Subtropicaly Mediterránea La Mayora, Universidad de Málaga-CSIC, E-29071 Málaga, Spain; [email protected] (E.D.); [email protected] (A.H.) 5 Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, E-29071 Málaga, Spain 6 Smart Materials, Istituto Italiano di Tecnologia, 16163 Genova, Italy; [email protected] (S.G.-P.); [email protected] (A.A.) * Correspondence: [email protected] (J.J.B.); [email protected] (J.A.H.-G.); Tel: +34-95448-9551 (J.J.B.); +39-0107-1781-276 (J.A.H.-G.) Received: 17 October 2018; Accepted: 6 November 2018; Published: 7 November 2018 Abstract: A method consisting of the alkaline hydrolysis of tomato pomace by-products has been optimized to obtain a mixture of unsaturated and polyhydroxylated fatty acids as well as a non-hydrolysable secondary residue. Reaction rates and the activation energy of the hydrolysis were calculated to reduce costs associated with chemicals and energy consumption. -
Proposed FDA Rule to Ban Partially Hydrogenated Vegetable Oils
Proposed FDA Rule To Ban Partially Hydrogenated (PHO) Oils Johari Minal [email protected] Outline • Chronology of events • The harmful effects of trans fats • The alternatives Background • 1957 – Fred Kummerow published paper against trans fats • 1968 – Asked AHA and ISEO to reduce trans fats • November 17, 1999 FDA proposed rule on “Food Labeling: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims • July 11, 2003 FDA issued a final rule on nutrition labeling regulations to require declaration of the trans fatty acid content, effective Jan 1, 2006 • 2004 - CSPI requested FDA to revoke the GRAS status of PHOs • August 28, 2009 Fred Kummerow filed a petition to FDA to ban trans fat • November 7, 2013, the US Food and Drug Administration (FDA) announced it is now considering removing partially hydrogenated oils (PHO)—the primary source of trans fats—from the list of “generally recognized as safe” (GRAS) ingredients. • Became globals news • If finalized, this would mean that food manufacturers would no longer be permitted to sell PHOs, either directly or as ingredients in another food product, without prior FDA approval for use as a food additive. Adverse Effects of Trans Fatty Acids PHOs could be harmful (i.e., increased risk for there is no threshold intake level for CHD) under any condition of use in food industrially-produced trans fat that would not increase an individual's risk of CHD risk factors for CHD - increased LDL-C levels and stronger effect on the risk of CHD than an increased risk of CHD -
Lipid Glossary 2 Was Published by the Oily Press in 2004 and Is Available Free of Charge from the Publisher's Web Site
This electronic version of Lipid Glossary 2 was published by The Oily Press in 2004 and is available free of charge from the publisher's web site. A printed and bound hardback copy of the book can also be purchased from the web site: www.pjbarnes.co.uk/op/lg2.htm LIPID GLOSSARY 2 Frank D. Gunstone Honorary Professor, Scottish Crop Research Institute, Dundee, UK Bengt G. Herslöf Managing Director, Scotia LipidTeknik AB, Stockholm, Sweden THE OILY PRESS BRIDGWATER ii Copyright © 2000 PJ Barnes & Associates PJ Barnes & Associates, PO Box 200, Bridgwater TA7 0YZ, England Tel: +44-1823-698973 Fax: +44-1823-698971 E-mail: [email protected] Web site: http://www.pjbarnes.co.uk All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted by any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission in writing from the publisher. All reasonable care is taken in the compilation of information for this book. However, the author and publisher do not accept any responsibility for any claim for damages, consequential loss or loss of profits arising from the use of the information. ISBN 0-9531949-2-2 This book is Volume 12 in The Oily Press Lipid Library Publisher's note: Lipid Glossary 2 is based on A Lipid Glossary, which was published by The Oily Press in 1992 (ISBN 0-9514171-2-6). However, Lipid Glossary 2 is more than simply a revised and updated edition of the earlier book — it is also much extended, with more than twice as many pages, and a much greater number of graphics (see Preface).